This inventor holds 8 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Agency for Science, Technology and Research, Chugai Seiyaku Kabushiki Kaisha, Nanyang Technological University. Active years: 2019-2026.
Company Filing History:
7 out of 1,557 
6 out of 985 
1 out of 679 
Years Active: 2019-2026
Title: The Innovations of Katja Fink: Pioneering Anti-Dengue and Zika Virus Treatments
Introduction
Katja Fink is a notable inventor based in Singapore, recognized for her significant contributions to the field of biotechnology. With a portfolio of seven patents, she has focused her research on developing innovative solutions for serious viral infections, particularly those related to dengue and Zika viruses. Her work has the potential to impact public health positively, especially in regions where these viruses are prevalent.
Latest Patents
Among her latest patents, Katja has developed anti-dengue virus antibodies and polypeptides containing variant Fc regions. This groundbreaking disclosure provides anti-Dengue virus (DENV) antibodies, methods for their production, and their applications in treating DENV infections. Additionally, her patents encompass nucleic acids encoding these antibodies and the host cells that contain them. The polypeptides developed include a variant Fc region with particular amino acid alterations that maintain efficacy while reducing binding activity to certain receptors. Furthermore, her innovation includes anti-DENV antibodies that exhibit cross-reactivity to the Zika virus (ZIKV), providing vital methods for the treatment and prevention of ZIKV infections.
Career Highlights
Katja has worked at prominent organizations such as the Agency for Science, Technology and Research (A*STAR) and Chugai Seiyaku Kabushiki Kaisha, where she has honed her expertise in the biotech space. Her work at these institutions has positioned her at the forefront of scientific research and development, as she continues to make significant strides in her field.
Collaborations
Throughout her career, Katja has collaborated with esteemed colleagues, including Roland Zuest and Xing'er Christine Koo. These collaborations have enabled her to achieve notable milestones in her research and patent development, fostering a collaborative environment that is essential for innovation.
Conclusion
Katja Fink's contributions to biotechnology, specifically in the realm of anti-viral treatments, underscore her role as a leading inventor in the field. With her impressive track record and ongoing research, she is well-positioned to continue making impactful advancements in the fight against viral infections, ultimately benefitting public health initiatives worldwide.